PierianDx Announces Expanded Partnership with Illumina to Support Cancer Genomic Reporting in Global Markets
1.12.2020 19:00:00 EET | Business Wire | Press release
PierianDx, the leading clinical genomics informatics company, today announced an expanded partnership with Illumina to enable PierianDx genomic reporting solutions for use with AmpliSeq™ for Illumina ® Focus Panel, AmpliSeq™ for Illumina ® Myeloid Panel and the TruSight™ Hereditary Cancer Panel. Adding these panels expands the existing relationship between Illumina and PierianDx, which currently covers use of the PierianDx platform to support genomic reporting in key global markets for the TruSight Oncology 500 portfolio.
Performing a comprehensive NGS test and delivering an accompanying genomic report were once only accomplished via a send-out test to a commercial lab. However, in performing tests as send-outs, healthcare organizations relinquish control over samples, turnaround time, and quality. The PierianDx platform enables healthcare organizations to accelerate their precision medicine programs by empowering them to create accurate, timely, and comprehensive clinical genomic reports in-house.
Illumina’s Senior Vice President and Chief Medical Officer Dr. Phil Febbo said: “PierianDx has demonstrated its commitment to best-in-class variant reporting solutions. We are excited to expand our partnership to cover the AmpliSeq™ suite of panels which are optimized for clinical cancer research.”
PierianDx develops Clinical Genomics Workspace™, which consists of intuitive software and a robust clinical knowledgebase which transforms unstructured variant information into a highly structured and usable clinical genomic report. In use by academic medical centers, cancer centers, reference laboratories, and healthcare organizations worldwide, it helps users accurately and rapidly classify and interpret variants to produce a physician-ready report.
Lincoln Nadauld, Vice President and Chief of Precision Medicine and Genomics, Intermountain Healthcare, explains, “Our partnership with PierianDx has enabled us to advance our precision medicine program by enhancing the classification of variants, accelerating the identification of targeted therapies, and expanding clinical trial opportunities for our patients.”
About PierianDx
Founded in 2014 out of Washington University in St. Louis, PierianDx is focused on advancing cancer diagnostics and making targeted therapeutics more accessible to healthcare systems, laboratories, and patients worldwide. Its industry-leading clinical genomics technologies, CAP and CLIA accredited laboratory, IVD-ready knowledgebase and reporting solution, and expertise deliver the most integrated, trusted, and collaborative approach across the clinical care spectrum. From genomic sequencing and biomedical informatics in the laboratory to reporting and decision support at the patient’s bedside, PierianDx drives the adoption of genomics in clinical care and accelerates the fight against somatic cancer and hereditary germline diseases. www.pieriandx.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201201005427/en/
Contact information
Lisa Owen
lowen@pieriandx.com
Cell : 206-851-6246
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Samos Energy Acquisition Corporation Announces Pricing of Initial Public Offering10.7.2026 16:32:00 EEST | Press release
Samos Energy Acquisition Corporation (the “Company”) announced today the pricing of its initial public offering (“IPO”) of 20,000,000 units at a price of $10.00 per unit. The units will be listed on the New York Stock Exchange (the “NYSE”) and trade under the ticker symbol “SAMO.U” beginning on July 10, 2026. Each unit consists of one Class A ordinary share and one-half of one redeemable warrant, with each whole warrant entitling the holder thereof to purchase one of the Company’s Class A ordinary shares at an exercise price of $11.50 per share. Once the securities comprising the units begin separate trading, the Class A ordinary shares and warrants are expected to be listed on the NYSE under the symbols “SAMO” and “SAMO.WS,” respectively. Cantor Fitzgerald & Co. is acting as the sole book running manager for the proposed offering. The Company has granted the underwriter a 45-day option to purchase up to an additional 3,000,000 units at the IPO price. The public offering is being made
Onera hPSG ® Wins Prestigious Red Dot Product Design Award10.7.2026 16:00:00 EEST | Press release
Onera Health, a leader in transforming sleep medicine, announces that its innovative product, Onera hPSG®, has been honoured with the prestigious Red Dot Product Design Award for 2026. This international recognition celebrates exceptional design quality and underscores Onera Health's commitment to excellence, creativity, and patient-centric innovation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260710266668/en/ Onera Health's patch-based home polysomnography solution, Onera hPSG®, wins Prestigious Red Dot Product Design Award 2026. The Red Dot Award, one of the most sought-after seals of quality for good design, attracted thousands of entries from around the globe. Onera hPSG® stood out for outstanding functionality, striking aesthetics, and thoughtful user experience. The expert jury praised the product for translating complex sleep diagnostics into a wearable, easy-to-use system that enables low-threshold application.
teamLab Biovortex Kyoto Welcomes Over 1 Million Visitors within 9 Months of Opening10.7.2026 10:00:00 EEST | Press release
teamLab Biovortex Kyoto has welcomed over 1 million visitors as of July 6, 2026, 9 months after its grand opening. (*1) These visitors arrived from more than 150 countries and regions. International visitors account for approximately 42% of the total. Many of these international visitors travel from distant countries and regions, including the United States, Australia, Canada, the United Kingdom, and Germany. Approximately 30% of these international visitors purchase their tickets at least 30 days in advance. teamLab Biovortex Kyoto is teamLab's largest museum in Japan, with an average visitor stay of over two and a half hours. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260709913938/en/ teamLab Biovortex Kyoto Welcomes Over 1 Million Visitors within 9 Months of Opening *1 According to ticket purchase data from the official teamLab Biovortex Kyoto website (survey period: October 7, 2025 – July 6, 2026) Visitors Comment (M
Robbyant Launches LingBot-VA 2.0 Built Natively for Embodied AI and Physical World Control10.7.2026 09:48:00 EEST | Press release
Robbyant, an embodied AI company within Ant Group, today announced the release of LingBot-VA 2.0, the industry’s first embodied-native video-action world model. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260709654440/en/ A robot powered by LingBot-VA 2.0 engages in a real-time tabletop air hockey match with a human This release marks a key transition in robotics foundation models, shifting from repurposing digital world models to designing them natively for the physical world. Instead of relying on fine-tuned digital content generation models, LingBot-VA 2.0 is built from scratch to meet the original demands of dynamic modeling, causal prediction, and real-time execution in physical environments. Integrating world models with embodied AI has been one of the major focuses of the AI industry. However, most mainstream approaches rely on video generation models designed for digital content, which are then fine-tuned for robo
SureWerx Appoints Erik Pertot as VP/GM SureWerx EMEA10.7.2026 09:00:00 EEST | Press release
SureWerx, a leading global manufacturer of personal protective equipment, safety products, tools and equipment solutions, today announced the appointment of Erik Pertot as VP/GM SureWerx EMEA. Pertot will report directly to CEO Scott Dowell and will lead growth, manufacturing and M&A activities in Europe across the company’s global portfolio. Erik joins SureWerx with more than 20 years of international leadership experience across engineering, quality, marketing, sales, international supply chain, product management, and general management. He brings deep expertise in the personal protective equipment industry, with a track record of leading complex, compliance-critical programs, managing business transitions, and driving growth across multinational environments. Most recently, Pertot served as Global General Manager for Footwear and Fall Protection at Protective Industrial Products (PIP), where he also held senior portfolio management leadership roles. Prior to that, he held a series
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom